MedTrace Logo

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

NCT02970019 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-03-31

No results posted yet for this study

Summary

This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease

Conditions

  • Parkinson Disease

Interventions

DRUG

K0706

Once a day administration after fast

DRUG

Placebo

Once a day administration after fast

Sponsors & Collaborators

  • Sun Pharma Advanced Research Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-30
Primary Completion
2019-05-28
Completion
2019-05-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02970019 on ClinicalTrials.gov